Healthcare software has lost roughly $100 billion of equity value in twelve months, and it has lost it while beating earnings. That is not a judgment on execution. It is the market repricing the terminal value of a delivery model – the one-size-fits-all package, lightly configured, priced by the seat – at the precise moment agentic AI makes institution-specific software economical for the first time. The value released by that shift is larger than the value destroyed. Capturing this value will require transactions and overcoming the cognitive biases of both buyers and sellers that routinely derail life sciences M&A, now intensified by the unprecedented transformation, growth and hype of Health AI.
The metabolic medicine sector is rapidly expanding and evolving beyond its traditional focus on diabetes toward obesity, cardiometabolic conditions, and rare metabolic diseases, driven by the success of incretin-based therapies and growing global disease burden.
Highlights, Trends & Opportunities
Highlights, Trends & Opportunities
Highlights, Trends & Opportunities
Gain insights into the latest M&A trends, key industry drivers, breakthroughs, and an outlook for 2025.
Highlights, Trends, Opportunities & Outlook
Highlights, Trends, Opportunities & Outlook
The Transformation of Virtual Care
Highlights, Trends, Opportunities & Outlook
Highlights, Trends, Opportunities & Outlook
Highlights, Trends, Opportunities & Outlook
Highlights, Trends, Opportunities & Outlook
How The HealthTech Industry Is Entering A (Probable) Recession, And Ways Management Teams Can Navigate Newly Unchartered Waters
Outcome Capital shares their analysis and insights on pivotal trends and opportunities within the Pharma Contract Services sector.
Outcome Capital shares their analysis and insights on pivotal trends and opportunities within the Digital Health sector.
Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the Medical Device sector.
Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the biopharma sector. This segment is poised for significant growth, scientific advancement and consolidation.
Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the life science consulting sector. This vibrant segment is poised for significant growth and consolidation.
Would you like to learn more about working with Outcome Capital or discuss your specific needs?